The Leader trial (the Lung Cancer Mutation Consortium) has developed a collaborative protocol to screen patients suffering from stage IA2-IIIA NSCLC through tissue- or blood-NGS for assessing the incidence of 10 molecular gene drivers, including ALK, in early-stage disease (NCT04712877). Here, ALK is linked to non-small cell lung carcinoma.